ABBVIE
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT06682988
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 88
- Registration Number
- NCT06673238
- Locations
- 🇺🇸
Acpru /Id# 270279, Grayslake, Illinois, United States
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 165
- Registration Number
- NCT06667687
- Locations
- 🇯🇵
The Cancer Institute Hospital Of JFCR /ID# 267470, Koto-ku, Tokyo, Japan
🇺🇸Carolina BioOncology Institute /ID# 265259, Huntersville, North Carolina, United States
🇺🇸START Mountain Region /ID# 267592, West Valley City, Utah, United States
Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting
- Conditions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT06639620
- Locations
- 🇫🇷
Les Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre /ID# 266843, Strasbourg, Alsace, France
🇫🇷Centre Hospitalier Régional Universitaire de Lille - Hôpital Roger Salengro /ID# 265954, Lille, Hauts-de-France, France
🇫🇷Clinique Beausoleil /ID# 266920, Montpellier, Herault, France
A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT06632938
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital /ID# 264785, Shanghai, Shanghai, China
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06632951
- Locations
- 🇺🇸
Highlands Oncology Group - Springdale /ID# 270290, Springdale, Arkansas, United States
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT06628310
- Locations
- 🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸Hattiesburg Clinic /ID# 268572, Hattiesburg, Mississippi, United States
🇺🇸Millennium Research & Clinical Development /ID# 268540, Houston, Texas, United States
A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 106
- Registration Number
- NCT06618118
- Locations
- 🇺🇸
CenExel CNR /ID# 265866, Sherman Oaks, California, United States
🇺🇸Clinical Neuroscience Solutions - Orlando - East South Street /ID# 265060, Orlando, Florida, United States
🇺🇸CenExel iResearch, LLC /ID# 265886, Decatur, Georgia, United States
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 460
- Registration Number
- NCT06614192
- Locations
- 🇺🇸
Northwestern University Robert H. Lurie Comprehensive Cancer Center /ID# 268610, Chicago, Illinois, United States
🇮🇱The Chaim Sheba Medical Center /ID# 267741, Ramat Gan, Tel-Aviv, Israel
🇺🇸Hope And Healing Cancer Services /ID# 268541, Hinsdale, Illinois, United States
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 160
- Registration Number
- NCT06605599
- Locations
- 🇵🇷
BDH Research /ID# 267025, San Juan, Puerto Rico
🇺🇸Harmonex /ID# 267504, Dothan, Alabama, United States
🇺🇸Axiom Research /ID# 267518, Colton, California, United States